Why the study?
It was unclear whether beta-blocker treatment is advantageous in patients with stable CAD who underwent PCI.
Does long-term beta-blocker therapy reduce major adverse cardiovascular events in patients with stable coronary artery disease without prior myocardial infarction or heart failure who underwent percutaneous coronary intervention?
Population
78,380 stable CAD patients without current or prior MI or heart failure undergoing DES implantation
Comparison
Beta-blocker treatment vs no beta-blocker treatment
Design
Nationwide cohort study
Follow-up
5 years
Authors
Loading...
Beta-blockers were associated with higher MACE risk post-PCI in stable CAD without prior MI/HF; leaves open whether RCTs would confirm causality or no benefit.
Does long-term beta-blocker therapy reduce major adverse cardiovascular events in patients with stable coronary artery disease without prior myocardial infarction or heart failure who underwent percutaneous coronary intervention?
In patients with stable CAD without prior MI or HF undergoing PCI, long-term beta-blocker therapy was not associated with improved clinical outcomes and showed a slightly higher risk of MACE.
Lee et al. (2022) studied this question.